← Compare landing
Merck KGaA vs SK pharmteco
Side-by-side profile data from each company listing. Missing fields stay blank rather than filled with assumptions.
| Category | Merck KGaA | SK pharmteco |
|---|---|---|
| Summary | Recent coverage reports that Merck KGaA plans to sell its life science CDMO business to Lonza. The same coverage describes a new €300 million bioprocessing center in Daejeon, South Korea. | SK pharmteco is a CDMO offering comprehensive drug development and manufacturing services. |
| Services | Data not yet provided. |
|
| Modalities | Data not yet provided. |
|
| Development capabilities | Data not yet provided. |
|
| Manufacturing capabilities | Data not yet provided. |
|
| Locations |
|
|
| Certifications | Data not yet provided. | Data not yet provided. |
Find similar companies
Markdown mirror: /compare/merck-kgaa/skpharmteco.md